Tag Archives: polycythemia vera

Novartis: EU approval for Jakavi® for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea

Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with an overproduction of blood cells that can lead to serious cardiovascular complications … Read the full press release

Novartis: CHMP of the European Medicines Agency adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib) significantly improved hematocrit levels and reduced spleen size, key measures of disease control[2] … Read the full press release